laitimes

Haite Biotech: Shadong has not carried out research and development and patents related to TNFR2

On May 12, the Financial Research Center of 300033 asked Haite Biotech (300683), what is the essential difference and correlation between Shadong's CPT drug and tumor necrosis factor receptor 2 (TNFR2) target drugs? Does the company have relevant research and development and drug patents for tumor necrosis factor receptor 2 (TNFR2) target drugs?

The company replied that thank you for your interest in the company. The essential difference between the two is that the classification and target are different, CPT is a cyclic allosteric TRAIL, and the TNFR2 target drug is TNF. TNFR2 is widely distributed in humans and plays an important role in inflammatory immunomodulation after binding to receptors, while CPT is specifically selected to induce apoptosis of tumor cells. Shadong did not conduct research and development and patents related to TNFR2. Thank you.

This article originated from the Flush Financial Research Center

Read on